These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1604485)

  • 1. Blocking of mononuclear cell accumulation, cytokine production, and endothelial activation within rat cardiac allografts by CD4 monoclonal antibody therapy.
    Hancock WW; Sayegh MH; Sablinski T; Kut JP; Kupiec-Weglinski JW; Milford EL
    Transplantation; 1992 Jun; 53(6):1276-80. PubMed ID: 1604485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cell activation, cytokine production, and cell adhesion.
    Schmidbauer G; Hancock WW; Wasowska B; Badger AM; Kupiec-Weglinski JW
    Transplantation; 1994 Mar; 57(6):933-41. PubMed ID: 8154043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of nondepleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts.
    Binder J; Lehmann M; Graser E; Hancock WW; Watschinger B; Onodera K; Sayegh MH; Volk HD; Kupiec-Weglinski JW
    Transplantation; 1996 Mar; 61(5):804-11. PubMed ID: 8607187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation.
    Hancock WW; Sayegh MH; Kwok CA; Weiner HL; Carpenter CB
    Transplantation; 1993 May; 55(5):1112-8. PubMed ID: 8497891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of a clinically relevant protocol to induce tolerance of cardiac allografts. Perioperative donor spleen cells plus cyclosporine suppress IL-2 and interferon-gamma production.
    Salom RN; Maguire JA; Hancock WW
    Transplantation; 1993 Dec; 56(6):1309-14. PubMed ID: 8278994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine and anti-interleukin 2 receptor monoclonal antibody therapy suppress accelerated rejection of rat cardiac allografts through different effector mechanisms.
    Hancock WW; DiStefano R; Braun P; Schweizer RT; Tilney NL; Kupiec-Weglinski JW
    Transplantation; 1990 Feb; 49(2):416-21. PubMed ID: 2106180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of BWH-4 anti-CD4 monoclonal antibody on rat vascularized cardiac allografts before and after engraftment.
    Sayegh MH; Sablinski T; Tanaka K; Kut JP; Kwok CA; Tilney NL; Kupiec-Weglinski JW; Milford EL
    Transplantation; 1991 Feb; 51(2):296-9. PubMed ID: 1704648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-depleting anti-CD4, but not anti-CD8, antibody induces long-term survival of xenogeneic and allogeneic hearts in alpha1,3-galactosyltransferase knockout (GT-Ko) mice.
    Chong AS; Ma L; Yin D; Shen J; Blinder L; XiuLong X; Williams JW; Byrne G; Diamond LE; Logan JS
    Xenotransplantation; 2000 Nov; 7(4):275-83. PubMed ID: 11081762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. alpha/beta-T cell receptor-directed therapy in rat allograft recipients. Long-term survival of cardiac allografts after pretreatment with R73 mAb is associated with upregulation of Th2-type cytokines.
    Heidecke CD; Hancock WW; Westerholt S; Sewczik T; Jakobs F; Zantl N; Varzaru A; Siegling A; Kurrle R; Deusch K; Volk HD; Kupiec-Weglinski JW
    Transplantation; 1996 Mar; 61(6):948-56. PubMed ID: 8623165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4 mAb therapy modulates alloantibody production and intracardiac graft deposition in association with selective inhibition of Th1 lymphokines.
    Kupiec-Weglinski JW; Wasowska B; Papp I; Schmidbauer G; Sayegh MH; Baldwin WM; Wieder KJ; Hancock WW
    J Immunol; 1993 Nov; 151(9):5053-61. PubMed ID: 8409456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of donor specific transplantation tolerance to cardiac allografts following treatment with nondepleting (RIB 5/2) or depleting (OX-38) anti-CD4 mAb plus intrathymic or intravenous donor alloantigen.
    Arima T; Lehmann M; Flye MW
    Transplantation; 1997 Jan; 63(2):284-92. PubMed ID: 9020332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymus-dependent, anti-CD4-induced tolerance to rat cardiac allografts.
    Jaques BC; Ahmiedat H; Alastair Gracie J; Marshall HE; Middleton SE; Bolton EM; Bradley JA
    Transplantation; 1998 Nov; 66(10):1291-9. PubMed ID: 9846511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of IL 2R+ T cells and macrophages within rejecting rat cardiac allografts, and comparison of the effects of treatment with anti-IL 2R monoclonal antibody or cyclosporin.
    Hancock WW; Lord RH; Colby AJ; Diamantstein T; Rickles FR; Dijkstra C; Hogg N; Tilney NL
    J Immunol; 1987 Jan; 138(1):164-70. PubMed ID: 3097143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of acute murine cardiac allograft rejection: anti-CD4 or anti-vascular cell adhesion molecule one monoclonal antibodies block acute rejection but permit persistent graft-reactive alloimmunity and chronic tissue remodelling.
    Orosz CG; Huang EH; Bergese SD; Sedmak DD; Birmingham DJ; Ohye RG; VanBuskirk AM
    J Heart Lung Transplant; 1997 Sep; 16(9):889-904. PubMed ID: 9322138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory effects of the alkaloid sinomenine in the high responder ACI-to-Lewis cardiac allograft model.
    Candinas D; Mark W; Kaever V; Miyatake T; Koyamada N; Hechenleitner P; Hancock WW
    Transplantation; 1996 Dec; 62(12):1855-60. PubMed ID: 8990376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-gamma in rat recipients of cardiac allografts.
    Wieder KJ; Hancock WW; Schmidbauer G; Corpier CL; Wieder I; Kobzik L; Strom TB; Kupiec-Weglinski JW
    J Immunol; 1993 Jul; 151(2):1158-66. PubMed ID: 8335897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2.
    Onodera K; Chandraker A; Volk HD; Ritter T; Lehmann M; Kato H; Sayegh MH; Kupiec-Weglinski JW
    Transplantation; 1999 Jul; 68(2):288-93. PubMed ID: 10440403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF antibody modulates cytokine and MHC expression in cardiac allografts.
    Wei RQ; Schwartz CF; Lin H; Chen GH; Bolling SF
    J Surg Res; 1999 Feb; 81(2):123-8. PubMed ID: 9927530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of murine cardiac allograft rejection with gallium nitrate. Comparison with anti-CD4 monoclonal antibody.
    Orosz CG; Wakely E; Bergese SD; VanBuskirk AM; Ferguson RM; Mullet D; Apseloff G; Gerber N
    Transplantation; 1996 Mar; 61(5):783-91. PubMed ID: 8607184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged murine cardiac allograft acceptance: characteristics of persistent active alloimmunity after treatment with gallium nitrate versus anti-CD4 monoclonal antibody.
    Orosz CG; Wakely E; Sedmak DD; Bergese SD; VanBuskirk AM
    Transplantation; 1997 Apr; 63(8):1109-17. PubMed ID: 9133472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.